ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of September 30, 2023
04 Ottobre 2023 - 6:00PM
Business Wire
Regulatory News:
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT),
a clinical stage biopharmaceutical company dedicated to the
development of innovative treatments for cardiovascular
emergencies, including ischemic stroke, today discloses the total
number of voting rights and shares as of September 30, 2023
(pursuant to Article L. 233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the French Financial
Markets Authority).
- Listing Place: Euronext Growth Paris
- ISIN Code : FR0014005OJ5
- Web site: acticor-biotech.com
Date
Number of shares making up the
share capital
Theoretical number of voting
rights (1)
Number of voting rights excluding
shares stripped of voting rights (2)
September 30, 2023
12.338.781
12.338.781
12.287.961
(1) In accordance with Article 223-111 of the AMF’s
General Regulation, this number of shares is calculated based on
all shares carrying the right to vote, including those stripped of
voting rights. (2) The actual voting rights correspond
to the total number of voting rights that can be exercised in a
general meeting. They are calculated on the basis of the total
number of voting rights attached to the total number of shares
minus the shares without voting rights.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
The positive results from its Phase 1b/2a study, ACTIMIS,
confirmed the safety profile and showed a reduction in mortality
and intracerebral hemorrhage in the glenzocimab-treated group in
patients with stroke. The efficacy of glenzocimab is now being
evaluated in an international Phase 2/3 study, ACTISAVE. In July
2022, Acticor Biotech was granted "PRIME" status by the European
Medicines Agency (EMA) for glenzocimab in the treatment of stroke.
This designation will allow the company to strengthen its
interactions and obtain early dialogues with regulatory
authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231004632126/en/
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD General Manager and CSO
Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Grafico Azioni Acticor Biotech (EU:ALACT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Acticor Biotech (EU:ALACT)
Storico
Da Mag 2023 a Mag 2024